The first facility in Arizona to offer a noninvasive procedure for the treatment of a patient's symptomatic uterine tumors is scheduled to open mid October. ExAblate of Phoenix LLC will be available to local gynecologists to perform the nonsurgical treatment of uterine fibroids. The non-invasive procedure uses the ExAblate 2000 system, which received US FDA approval in October 2004.
"The ExAblate technology combines magnetic resonance imaging and focused ultrasound surgery (MRgFUS), which enables us to not only see the fibroid and surrounding organs in 3-D, but to destroy the targeted tumors inside the body without the need for traditional surgical incisions,” said Dr. Robert Gallai, M.D., FRCS(C), FACOG, medical director for ExAblate of Phoenix. “On average, patients return to normal activities in one to two days. Other surgical treatments for fibroids are invasive and can require several days of hospital stay and up to six weeks of recovery time."


Related Content

News | Radiology Business

April 4, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time April 04, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | FDA

March 27, 2024 — SyntheticMR announced that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) ...

Time March 27, 2024
arrow
News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
News | Radiology Business

January 25, 2024 — Esaote Group, a leading Italian innovator in medical imaging, today unveiled its new brand identity ...

Time January 25, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
News | Artificial Intelligence

December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based ...

Time December 22, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

December 20, 2023 — Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for ...

Time December 20, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Subscribe Now